Effect of 131I-labeled G250 monoclonal antibody on the nude mice bearing human renal cancer

OBJECTIVE: To study the distributions of 131I-G250McAb in nude mice bearing human renal cancer, and explore the feasibility and efficacy of 131I-G250 in treating experimental human renal cancer. METHODS: After the animal models were established, 1 mL 131I-G250(3.7MBq) was injected through their tail veils. Radioactivity in tissue was measured at certain time after injection. The distribution of 131I-G250 was measured by comparing the radioactivity of tumor with the radioactivity of non-tumor (T/NT). Sixteen nude mices were divided into four groups (A, B, C, D) according to gender, weight and the tumor volume. After injection, tumor growth was monitored for one month. RESULTS: More radioactivity accumulated in the tumor and the highest T/NT radioactivity ratio was 5.0(tumor/muscle). The percentage of injected dose per gram (%ID/g) reached the peak with 8.61±0.29 at 48h after injection. One month later, the volume of the tumor in 131I-G250 group was (0.77±0.04) cm 3, while in 0.9%NaCl group was (2.04±0.18), Na 131I group and G250 I group were (1.85±0.11) and (1.81±0.22) cm 3 respectively. The volume of the tumor in B group was significantly reduced compared to other three groups (F=76.14, P<0.05). CONCLUSION: The results demonstrate that 131I-G250 can specifically accumulate in the tumor and effectively inhibit its growth.